tiprankstipranks

Jeffrey Scott Riley Insider Profile

4 Followers
Jeffrey Scott Riley, CEO, Director at Theriva Biologics, holds 30.00K shares in Gain Therapeutics (Ticker: GANX), holds 10.40K shares in Theriva Biologics (Ticker: TOVX). Most recently, Jeffrey Scott Riley Bought ― shares of Gain Therapeutics on Apr 01, 2024 for an estimated value of 115.50K.
tipranks
Jeffrey Scott Riley

Jeffrey Scott Riley
Theriva Biologics (TOVX)
CEO, Director

Not Ranked
Jeffrey Scott Riley has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$65K
79.49%
20.51%
A breakdown of Jeffrey Scott Riley's holdings

Insider Roles

Gain Therapeutics
(GANX)
Director
Theriva Biologics
(TOVX)
CEO, Director
Roles that Jeffrey Scott Riley holds in companies

Most Profitable Insider Trade

Stock:
Gain Therapeutics
(GANX)
Rating:Informative Buy
Date:Apr 01, 2024 - Today
Return:-42.10%
The most profitable trade made by Jeffrey Scott Riley

Jeffrey Scott Riley's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Theriva Biologics
Jan 07, 2013
CEO, Director
Informative Buy
500.70
$13.31K
Gain Therapeutics
Apr 01, 2024
Director
Informative Buy
115.50K
$51.60K
List of latest transactions for each holding click on a transaction to see Jeffrey Scott Riley's performance on stock

Jeffrey Scott Riley insider profile FAQ

What is the percentage of profitable transactions made by Jeffrey Scott Riley?
The percentage of profitable transactions made by Jeffrey Scott Riley is ―.
    What is the average return per transaction made by Jeffrey Scott Riley?
    The average return per transaction made by Jeffrey Scott Riley is ―.
      What stocks does Jeffrey Scott Riley hold?
      Jeffrey Scott Riley holds: TOVX, GANX stocks.
        What was Jeffrey Scott Riley’s latest transaction?
        Jeffrey Scott Riley latest transaction was an Informative Buy of $115.50K.
          What was Jeffrey Scott Riley's most profitable transaction?
          Jeffrey Scott Riley’s most profitable transaction was an Informative Buy of GANX stock on April 1, 2024. The return on the trade was -42.10%.
            What is Jeffrey Scott Riley's role in Theriva Biologics?
            Jeffrey Scott Riley's role in Theriva Biologics is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.